PM-1003

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NamePM-1003
Drug Alias NamePM1003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionImmunomodulatorsProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 9 agonists
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator Companies +[1]  N/A
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBaiouentai (Zhuhai) Pharmaceutical Research and Development Co Ltd +[2] 
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A